A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis
Clinical trial NCT04304144 · COMPLETED
Trial details
- NCT number
- NCT04304144
- Sponsor
- Alexion Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-03-18
- Primary completion
- 2023-11-14
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.